Overgrowth disorders are a heterogeneous group of conditions characterized by increased growth parameters and other variable clinical features such as intellectual disability and facial dysmorphism 1 . To identify new causes of human overgrowth, we performed exome sequencing in ten proband-parent trios and detected two de novo DNMT3A mutations. We identified 11 additional de novo mutations by sequencing DNMT3A in a further 142 individuals with overgrowth. The mutations alter residues in functional DNMT3A domains, and protein modeling suggests that they interfere with domain-domain interactions and histone binding. Similar mutations were not present in 1,000 UK population controls (13/152 cases versus 0/1,000 controls; P < 0.0001). Mutation carriers had a distinctive facial appearance, intellectual disability and greater height. DNMT3A encodes a DNA methyltransferase essential for establishing methylation during embryogenesis and is commonly somatically mutated in acute myeloid leukemia [2] [3] [4] . Thus, DNMT3A joins an emerging group of epigenetic DNA- and histone-modifying genes associated with both developmental growth disorders and hematological malignancies 5 .
Control of human growth is highly complex and is influenced by common and rare genetic variation 6 . The study of human overgrowth syndromes, which are characterized by increased prenatal and postnatal growth relative to age-related peers, has provided important insights into fundamental biological processes involved in growth control 1 . As many growth disorders present as non-familial cases with a distinctive phenotype, we hypothesized that de novo gene mutations might underlie some cases. To investigate this, we are conducting trio-based exome sequencing in individuals with overgrowth and their parents using the Illumina TruSeq exome enrichment array. Specifically, we perform sequencing with an Illumina HiSeq 2000, align the data with Stampy, perform variant calling with Platypus, perform variant annotation with SAVANT and identify potential de novo variants using a custom R script.
Review of the first ten trios identified two with apparent de novo mutations in DNMT3A (encoding DNA (cytosine-5)-methyltransferase 3A), which were of immediate interest because of the functional relationship of DNMT3A with EZH2, a known overgrowth predisposition gene mutated in Weaver syndrome 7, 8 . By Sanger sequencing, we confirmed that the DNMT3A mutations, which resulted in an in-frame deletion (p.Trp297del) in COG0274 and a nonsynonymous substitution (p.Leu648Pro) in COG0553, were present in the probands but not in their parents ( Table 1 and Supplementary Fig. 1 ).
To further evaluate the role of DNMT3A, we sequenced the full coding sequence and intron-exon boundaries of the gene by Sanger sequencing in an additional 142 individuals with overgrowth in whom mutations in NSD1, EZH2 and PTEN and dysregulation of the 11p15 growth-regulatory region had been excluded and for whom parental DNA was also available (Supplementary Table 1 ). We identified an additional 11 de novo DNMT3A mutations. Thus, in total, we found 13 different de novo DNMT3A mutations in 152 individuals with overgrowth phenotypes: 10 nonsynonymous mutations, 2 small frameshifting insertions and 1 in-frame deletion (Fig. 1, Table 1 and Supplementary Fig. 1 ). These data establish DNMT3A mutations l e t t e r S as a cause of a new human disorder that we have termed 'DNMT3A overgrowth syndrome' .
A consistent phenotype, characterized by a distinctive facial appearance, tall stature and intellectual disability, was evident among the 13 individuals with de novo DNMT3A mutations ( Fig. 2 and Table 1 ). Facial gestalt was characterized by a round face, heavy horizontal eyebrows and narrow palpebral fissures (Fig. 2) . Height was greater in all individuals, ranging from 1.8 to 4.2 (mean of 3.0) s.d. above the mean with reference to UK 1990 growth data 9 . Head circumference was also greater, ranging from 1.2 to 5.1 (mean of 2.5) s.d. above the mean. Intellectual disability, which was described as moderate in 11 individuals and mild in the remaining 2, is also a key feature of the condition. Other less frequent clinical features were variably present ( Table 1) . More detailed phenotyping in larger series is required to evaluate whether these features are consistently associated with DNMT3A mutations and to better define the clinical spectrum of this new overgrowth syndrome.
In eukaryotic DNA, methylation preferentially occurs at cytosine bases, which are converted to 5-methylcytosine by four DNA methyltransferase enzymes-DNMT3A, DNMT3B, DNMT1 and DNMT3L 2 . DNMT3A and DNMT3B are essential for establishing new methylation marks after the erasure of parental methylation patterns during early embryonic development and for establishing sex-dependent methylation marks for imprinted genes during gametogenesis [10] [11] [12] . In contrast, DNMT1 is essential for maintaining DNA methylation marks after DNA replication 11 . DNMT3L does not possess inherent enzymatic activity but appears to physically interact with DNMT3A and stimulate its enzymatic activity [13] [14] [15] .
DNMT3A contains three functional domains: a proline-tryptophan-tryptophan-proline (PWWP) domain, an ATRX-DNMT3A-DNMT3L-type zinc-finger (ADD) domain and a C-terminal DNA methyltransferase (MTase) domain (Fig. 1) . It is noteworthy that all the mutations we identified affected these functional domains, and none were present in 1,000 exomes from a UK population control series that were sequenced and analyzed in a similar fashion. Moreover, no other frameshifting or nonsynonymous mutations affecting these functional domains were present in the control exomes; four nonsynonymous variants were detected, but all mapped outside the functional domains ( Fig. 1) . These data provide further evidence that the DNMT3A mutations in cases are pathogenic (13/152 mutations in cases versus 0/1,000 in controls; P < 0.0001).
DNMT3A is one of the most frequently mutated genes in acute myeloid leukemia (AML) 3, 4, 16 . Somatic DNMT3A mutations are detected in approximately one-third of cytogenetically normal AML cases and have also been reported in other hematological neoplasms, such as myelodysplastic syndrome (MDS) 17, 18 . Over half of the somatic DNMT3A mutations target a single residue, Arg882, with the remainder being nonsynonymous and truncating mutations scattered throughout the gene 3, 16 . The somatic mutational spectrum thus differs from the de novo mutations we identified in overgrowth cases: we did not detect any mutations affecting Arg882, and only 2 of the mutations we report (resulting in p.Arg749Cys and p.Pro904Leu substitutions) were also present in the 167 confirmed somatic DNMT3A mutations in hematological malignancies listed in the Catalogue of Somatic Mutations in Cancer (COSMIC) database (Supplementary Table 2) .
Protein structure modeling suggests that the somatic mutations altering Arg882 affect DNA binding, and functional analyses have demonstrated that alterations at this residue result in reduced methyltransferase activity, possibly through a dominant-negative mechanism 4, 16, 19 . To explore the potential impact of the DNMT3A l e t t e r S mutations identified in overgrowth cases, we undertook protein structure modeling, in which the residues altered by nonsynonymous mutations in the MTase domain appeared to be located at the interaction interface with the ADD domain, whereas those in the ADD domain were close to the histone H3-binding region (Fig. 3) . The Arg767 residue in the MTase domain that was altered by a frameshifting insertion was situated at the interface between DNMT3A and DNMT3L. Thus, whereas none of the overgrowthassociated mutations appear likely to affect DNA binding, their positions and the role of the ADD domain in recognizing unmethylated lysine 4 of histone H3 suggest that they might interfere with domain-domain interactions and histone binding, thereby disrupting de novo methylation 20 . Taken together, these data are intriguing, as they show both clear differences and some overlap between the DNMT3A mutational spectra in malignancies and overgrowth. The mechanism of pathogenesis in the DNMT3A overgrowth syndrome is currently unclear, although a simple haploinsufficiency model appears unlikely given the small proportion of truncating mutations. Of note, mice heterozygous for a Dnmt3a null allele are grossly phenotypically normal, although it is unclear whether this is because loss of one copy of Dnmt3a is not associated with overgrowth or because the overgrowth phenotype is too subtle to detect in mice 10 . Further functional and mutational analyses will be of interest to extend and illuminate these observations. Long-term follow-up of individuals with DNMT3A overgrowth syndrome, with a particular focus on cancer incidence, will also be of interest. Thus far, none of the probands have developed malignancies, although the oldest is only 29 years of age. Hematological malignancies with somatic DNMT3A mutations typically occur in middle-aged individuals 3,4 , and it is thus possible that increased cancer risk only manifests at older ages.
DNMT3A joins an emerging family of genes with dual roles in the pathogenesis of syndromic overgrowth and myeloid neoplasms. Other similar genes include EZH2 and NSD1 (ref. 5 ). The overgrowth phenotypes associated with constitutional mutations in EZH2 and NSD1, which are called Weaver syndrome and Sotos syndrome, respectively, are similar to each other and to DNMT3A overgrowth syndrome 5, 8, 21 . Somatic EZH2 mutations, both activating and inactivating, occur in AML and in myeloproliferative neoplasms and myelodysplastic syndromes with poor prognosis 16, 22 . Somatic NSD1 point mutations are rare 4 , but the NUP90-NSD1 fusion protein, generated through a recurrent t(5;11)(q35.3;p15.5) translocation, is present in approximately 5% of childhood AML cases 23 . Both EZH2 and NSD1 are histone methyltransferases that have key roles in regulating transcription through histone modification and chromatin modeling. EZH2 catalyzes the trimethylation of lysine residue 27 in histone H3 (H3K27me3) and is associated with transcriptional repression, whereas NSD1 preferentially catalyzes methylation of lysine residue 36 of histone H3 (H3K36me1), which is primarily associated with transcriptional activation 24, 25 . Of note, another gene involved in chromatin modification that is often mutated in AML and MDS, ASXL1, is also associated with a growth disorder 16, 26 . Constitutional de novo truncating mutations of ASXL1 cause Bohring-Opitz syndrome, a rare disorder characterized by severe undergrowth, severe intellectual disability, a characteristic facial appearance and flexion deformities 26 . This suggests that other epigenetic regulatory genes that are somatically mutated in hematological malignancies, such as TET2, IDH1 and IDH2, would be worth evaluating in developmental growth disorders 16 .
URLs. 1958 Birth Cohort Collection, http://www.cls.ioe.ac.uk/; Picard, http://picard.sourceforge.net/.
MeThODS
Methods and any associated references are available in the online version of the paper.
Accession codes. DNMT3A mutation nomenclature corresponds to Ensembl transcript ENST00000264709. 
ONLINe MeThODS
Case subjects. Individuals with overgrowth were recruited through the Childhood Overgrowth Study. Statistical analysis. The frequencies of mutations in cases and controls were compared using a two-sided Fisher's exact test.
Protein structural modeling. The model of the DNMT3A-DNMT3L complex was created using the crystal structures of the DNMT3A ADD domain (Protein Data Bank (PDB) 3A1B), the DNMT3A MTase domain (PDB 2QRV) and full-length DNMT3L (PDB 2PVC). Bound DNA was positioned by superposing the crystal structure of bacterial cytosine methyltransferase HhaI in complex with DNA (PDB 1MHT). First, the structure of partial DNMT3L in complex with DNMT3A was superposed on the structure of full-length DNMT3L to show the interactions of full-length DNMT3L with DNMT3A. Subsequently, the ADD domain of DNMT3A was positioned by superposing it onto the homologous region of the second molecule of full-length DNMT3L. Finally, DNA was positioned by superposing the crystal structure of bacterial cytosine methyltransferase HhaI in complex with DNA onto the MTase domain of DNMT3A, placing the DNA at the SAM/DNA-binding region. The image was generated using PyMOL visualization software (PyMOL Molecular Graphics System, version 1.6.0.0, Schrödinger). 
